GLP1R and type 2 diabetes mellitus: Limited evidence from a large retrospective cohort study of 2025 observed statistical association between GLP-1 RA use and a reduced incidence of hematologic cancers, including leukemia and myelodysplastic syndromes, in patients with type 2 diabetes.